Latest News

ADAPs achieve 87% viral suppression but face funding crisis as multiple policies erode 340B rebates.

Medicare drug negotiation's third wave includes Biktarvy, raising HIV treatment access concerns.

FY2026 preserves HIV funding but level funding can't support long-acting therapeutics or growing needs.

State Prescription Drug Affordability Boards limit public input while basing pricing decisions on flawed methodologies.

Preview of 2023 federal regulatory priorities: Section 1557, IRA implementation, and prior authorization reform.

Final installment addressing 340B reform needs: transparency, accountability, and contract pharmacy concerns.

Analyzes Biden health policy priorities including drug pricing reform and Medicare expansion.